- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00862134
Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
The current understanding of PR104 justifies the evaluation of PR104 with docetaxel in subjects with Non Small Cell Lung Cancer (NSCLC). These include:
- Aldo-keto reductase 1C3 (AKR1C3). NSCLC has been shown to express high levels of AKR1C3 in about one half of tumors tested. Subjects with high levels of AKR1C3 should have increased activation of PR104 within their tumor.
- Hypoxia. NSCLC has been demonstrated to be a tumor with hypoxia based on both direct tumor measurements (oxygen electrodes) and hypoxic positron emission tomography (PET) imaging. Tumor hypoxia in NSCLC should be sufficient to activate PR104 to its active metabolites PR104H and PR104M.
- Preclinical data. The use of docetaxel and PR104 alone and in combination in preclinical models demonstrates activity of PR104 as a single agent and supraadditive activity when PR104 and docetaxel are used in combination.
- Manageable toxicity. PR104 and docetaxel with Granulocyte Colony-stimulating Factor (G-CSF) have been combined in a prior phase I study. A Maximum Tolerated Dose (MTD) has been identified and the major toxicities of this combination are understood.
The current study will provide an estimate of the activity of PR104 in subjects with NSCLC. This information will prove valuable in defining the future clinical development of PR104, and in determining if PR104 has sufficient activity in NSCLC to warrant a larger phase III registration study in this indication.
Primary objectives
• Estimate the response rate (RR) of PR104/docetaxel
Secondary objectives
- Evaluate survival
- Evaluate progression free survival (PFS)
- Evaluate time to progression (TTP)
- Evaluate safety
- Evaluate the pharmacokinetics of PR104 and its metabolites
- Evaluate the pharmacokinetics of docetaxel
- Evaluate the tumor hypoxia using 18F-fluoromisonidazole (18F-MISO) PET imaging
- Collect diagnostic biopsy samples for the determination of AKR1C3
- Collect plasma samples for assessment of potential biomarkers of tumor hypoxia
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
A randomized phase II, multi-center, open-label, study of docetaxel versus docetaxel/PR104.
Following informed consent, subjects will undergo baseline evaluation with history, physical exams, blood work and disease assessment. Selected subjects will undergo PET imaging with F18 fluoromisonidazole (F18-FMISO) and Fludeoxyglucose (FDG) for assessment of hypoxia and glucose metabolism, and pharmacokinetics of PR104.
Subjects will be randomized between arm 1 consisting of docetaxel, 75 mg/m^2, administered intravenously (IV), every 21 days (an approved dose and schedule) and arm 2 consisting of docetaxel, 60 mg/m^2 with PR104 at 770 mg/m^2, IV, every 21 days. Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF. One cycle will be 21 days in duration. Subjects will be evaluated weekly. A disease assessment will be performed every six weeks. Subjects with progression will be removed from study. Subjects with a response or stable disease may continue on study if this is considered beneficial by their physician.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University
-
-
-
-
-
Hamilton, Nouvelle-Zélande
- Waikato District Health Board
-
-
-
-
California
-
San Diego, California, États-Unis, 92123
- Sharp Clinical Oncology Research
-
-
Florida
-
Miami, Florida, États-Unis, 33136
- University of Miami/Sylvester Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
Skokie, Illinois, États-Unis, 60076
- Orchard Research, LLC
-
Zion, Illinois, États-Unis, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Beech Grove, Indiana, États-Unis, 46107
- St. Francis Health Services
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- McFarland Clinic/William R. Bliss Cancer Center
-
Cedar Rapids, Iowa, États-Unis, 52402
- Iowa Blood & Cancer Care
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Mt. Sterling, Kentucky, États-Unis, 40353
- Montgomery Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70809
- Baton Rouge General/Penington
-
-
Maryland
-
Annapolis, Maryland, États-Unis, 21401
- Annapolis Oncology Center
-
Baltimore, Maryland, États-Unis, 21215
- Lapidus Cancer Center/Sinai Hospital
-
-
Michigan
-
Kalamazoo, Michigan, États-Unis, 49048
- Kalamazoo Hematology & Oncology
-
-
Nevada
-
Reno, Nevada, États-Unis, 89502
- VA Sierra Nevada Health Care System
-
-
North Carolina
-
Durham, North Carolina, États-Unis
- VA Medical Center
-
Winston-Salem, North Carolina, États-Unis, 27103
- Piedmont Hematology Oncology Associates, PLLC
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45220
- Cincinnati VA Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis
- University of Pennsylvania
-
-
South Carolina
-
Columbia, South Carolina, États-Unis, 29209
- WJB Dorn VA Medical Center
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38120
- ACORN
-
-
Texas
-
Dallas, Texas, États-Unis, 75246
- Mary Crowley Medical Research Center
-
Fort Worth, Texas, États-Unis, 76104
- The Center for Cancer and Blood Disorders
-
Midland, Texas, États-Unis, 79701
- Texas Oncology - Allison Cancer Center
-
Temple, Texas, États-Unis, 76508
- Scott & White Memorial Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects with locally advanced or metastatic NSCLC (stage IIIb/IV) who have relapsed following adjuvant or first line therapy with a platinum containing regimen, and are appropriate candidates for treatment with single agent docetaxel
- Confirmed NSCLC by prior pathological analysis (tissue aspirate or biopsy)
- At least 21 days from prior chemotherapy
- At least 30 days from prior irradiation therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of 12 weeks or more
- Adequate hematologic function [Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; platelet count ≥100x10^9/L; hemoglobin ≥8.5 g /dL maintained in the absence of red blood cell transfusions; and prothrombin time international normalized ratio ≤1.7; or prothrombin time ≤2 seconds above control)
- Adequate hepatic function (albumin ≥2.8 g/dL; total bilirubin ≤2 mg/dL [51.3 μmol/L]; and alanine aminotransferase and aspartate aminotransferase ≤1.5 times the upper limit of the normal range)
- Adequate renal function (serum creatinine ≤2.0 times the upper limit of the normal range or creatinine clearance ≥60 mL/min).
- At least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
- Previous treatment with docetaxel (prior treatment with paclitaxel permitted)
- Receipt of more than one prior systemic chemotherapy regimen
- Active concomitant malignancy likely to effect any of the primary or secondary outcome measures in the current study
- Women who are pregnant, breast-feeding or planning to become pregnant during the study
- Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose
- Evidence of a significant medical disorder or laboratory finding that, in the opinion of the Investigator, compromises the subject's safety during study participation
- Active Central Nervous System (CNS) metastatic disease requiring intervention
- Less than 4 weeks since major surgery
- Known human immunodeficiency virus (HIV) positivity
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Docetaxel 75 mg/m^2
Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
|
75 mg/m^2, IV, every 21 days.
Number of Cycles: until progression or unacceptable toxicity develops.
Autres noms:
60 mg/m^2, IV, every 21 days.
Number of Cycles: until progression or unacceptable toxicity develops.
Autres noms:
|
|
Expérimental: PR104 + 60 mg/m^2 docetaxel
Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
|
75 mg/m^2, IV, every 21 days.
Number of Cycles: until progression or unacceptable toxicity develops.
Autres noms:
60 mg/m^2, IV, every 21 days.
Number of Cycles: until progression or unacceptable toxicity develops.
Autres noms:
770 mg/m^2, IV, every 21 days.
Number of Cycles: until progression or unacceptable toxicity develops.
Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations.
Number of Cycles: until progression or unacceptable toxicity develops.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants That Achieved a Response (Complete or Partial) After Receiving PR104/Docetaxel Versus Docetaxel Alone
Délai: Participants were followed for the duration on study, an average of 4 months
|
Defined as the number of subjects with complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
|
Participants were followed for the duration on study, an average of 4 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and Tolerability: Serious Adverse Events
Délai: 30 days following last administration of study treatment
|
The number of participants with at least one Serious Adverse Event was measured.
|
30 days following last administration of study treatment
|
|
Positive Aldo-keto Reductase 1C3 (AKR1C3) Expression in Participating Patients
Délai: Within 1 year of enrollment
|
AKR1C3 was evaluated on a semi-quantitative scale, and the percentage of cells staining at each of the following four levels was recorded: 0 (unstained), 1+ (weak staining), 2+ (moderate staining) and 3+ (strong staining). Patients with a strong staining score (3+) were considered to be AKR1C3 positive |
Within 1 year of enrollment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs pulmonaires
- Carcinome pulmonaire non à petites cellules
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents antinéoplasiques
- Facteurs immunologiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Adjuvants, immunologique
- Docétaxel
- Lénograstim
Autres numéros d'identification d'étude
- PR104-2003
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .